Today, on World Lung Cancer Day, we pause to recognize the strength of patients and survivors and to reflect on the critical need for continued research and innovation in lung cancer care. This annual observance shines a spotlight on the millions of people affected by lung cancer worldwide—and on the importance of expanding access to effective treatments, especially for complex complications like leptomeningeal metastases (LM).
At Plus Therapeutics, we are actively working to address this urgent need through our ReSPECT-LM clinical trial, which is evaluating REYOBIQ™ (rhenium Re186 obisbemeda) in patients with LM—a devastating complication of advanced cancers, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Although LM is considered rare, it is not uncommon in lung cancer:
-
Approximately 4% to 7% of people with NSCLC may develop LM.
-
For those with SCLC, the rate rises to about 11%.
These statistics underscore the importance of developing new, effective treatment strategies to improve outcomes for this vulnerable patient population.
To learn more about our ongoing ReSPECT-LM trial and how we are advancing radiotherapeutic innovations for CNS complications, visit: https://lnkd.in/gFnhc5Rv
We also honor the efforts of organizations like the LUNGevity Foundation, LiveLung, the Lung Cancer Research Foundation, and the Leptomeningeal Cancer Foundation, who continue to support patients and accelerate progress through advocacy and education.
#WorldLungCancerDay #LungCancer #LeptomeningealMetastases #ClinicalTrials #PSTV #ReSPECTLM #NSCLC #SCLC #NeuroOncology #CancerResearch #Radiotherapeutics
Recent Comments